Drug Profile
Mavorixafor - Sanofi/X4 Pharmaceuticals
Alternative Names: ABSK-081; AMD-070; AMD-11070; X4P 001 RD; X4P-001; X4P-001-IOLatest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator AnorMED
- Developer Abbisko Therapeutics; X4 Pharmaceuticals
- Class Antineoplastics; Antiretrovirals; Benzimidazoles; Diamines; Hydroquinones; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Waldenstrom's macroglobulinaemia
Highest Development Phases
- Preregistration WHIM syndrome
- Phase II Neutropenia
- Phase I/II Malignant melanoma; Renal cell carcinoma; Triple negative breast cancer
- Phase I Waldenstrom's macroglobulinaemia
- Preclinical Solid tumours
- Discontinued HIV-1 infections
Most Recent Events
- 09 Dec 2023 Updated efficacy and adverse events data from a phase II in Chronic neutropenia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 09 Dec 2023 Adverse events data from a phase I/II trial in Chronic neutropenia released by X4 Pharmaceuticals
- 31 Oct 2023 FDA assigns PDUFA action date of 30/04/2024 for mavorixafor for WHIM-syndrome.